Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788894 | 0.84 | CRHR1 (0.62) | CRHR1TDP1 | |
| SCHEMBL7783154 | 0.81 | CRHR1 (0.50) | CRHR1ALDH1A1 | |
| SCHEMBL7788921 | 0.80 | CRHR1 (0.49) | CRHR1ALDH1A1 | |
| SCHEMBL7788898 | 0.80 | CRHR1 (0.48) | CRHR1TDP1ALDH1A1 | |
| SCHEMBL7792997 | 0.80 | CRHR1 (0.54) | CRHR1TDP1ALDH1A1 | |
| SCHEMBL7557048 | 0.78 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL7792967 | 0.78 | CRHR1 (0.57) | CRHR1TDP1 | |
| SCHEMBL7788887 | 0.78 | CRHR1 (0.55) | CRHR1TDP1 | |
| SCHEMBL7783161 | 0.78 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL7788189 | 0.78 | CRHR1 (0.50) | CRHR1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NEUROGEN CORPORATION | 2001-10-18 | — | — | US | claimed |
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NEUROGEN CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-6221875-B1 | TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL | NEUROGEN CORPORATION | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NPY1R, NPY2R, NPY5R | CRHR1 33/4885TDP1 2365/4885ALDH1A1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.